Solara Active Pharma Sciences Limited , a prominent player in the pharmaceutical industry, continues to strengthen its employee incentive programs through strategic stock option allotments. The company's Board of Directors recently approved another allotment under the Solara Employee Stock Option Plan 2018.

Latest ESOP Allotment Details

On December 17, 2025, the Board of Directors approved the allotment of 1,500 equity shares under the employee stock option plan. The key details of this latest allotment are:

Updated Share Capital Structure

The allotment has resulted in changes to the company's share capital structure:

The newly allotted shares rank pari-passu with existing equity shares in all respects.

Previous ESOP Activities

This follows the company's earlier allotment of 8,040 equity shares in November 2025, which raised Rs. 30.15 lakhs. The company had also previously granted 25,000 stock options to employees with an exercise price of Rs. 375.00 per share and a structured vesting schedule over three years.

Financial Performance Context

The diluted earnings per share remains at Rs. 19.00 following this allotment. These employee stock option exercises are part of Solara's broader strategy to align employee interests with shareholder value while the company works on improving its financial performance and exploring strategic restructuring opportunities including the potential demerger of its CRAMS and Polymers business.

Regulatory Compliance

The allotment complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options were exercised within the prescribed 120-day period from the vesting date.

Solara Active Pharma Sciences has announced the reconstitution of its Management Committee following a board meeting held on December 17, 2025. The company communicated this development to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board of Directors approved the reconstitution of the Management Committee during their meeting on December 17, 2025. The decision was made to enhance governance structure and operational efficiency of the pharmaceutical company.

Management Committee Composition

The reconstituted Management Committee comprises three key members representing different levels of the organizational hierarchy, ensuring comprehensive oversight and decision-making capabilities.

Corporate Structure

The Management Committee reconstitution reflects the company's commitment to maintaining robust governance standards. Mr. Arun Kumar Pillai will lead the committee as Chairperson in his capacity as Non-Executive Director, while the Managing Director & CEO and Chief Financial Officer will serve as key members.

Regulatory Compliance

Solara Active Pharma Sciences has fulfilled its disclosure obligations by informing both major stock exchanges about the committee reconstitution. The company operates from its corporate office at TICEL Bio Park, Chennai, and maintains its registered office in Navi Mumbai.

The reconstitution demonstrates the company's ongoing efforts to strengthen its management structure and ensure effective oversight of operations across its pharmaceutical business segments.